Hypothalamic Obesity (HO) - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypothalamic Obesity pipeline landscape is provided which includes the disease overview and Hypothalamic Obesity treatment guidelines. The assessment part of the report embraces, in depth Hypothalamic Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypothalamic Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hypothalamic Obesity (HO) Understanding
According to Genetic and Rare Disease Information Centre, Hypothalamic Obesity (HO) is a complex neuroendocrine disorder that is caused by physical or inborn damage to the hypothalamus. Energy balance is regulated by a complex neuroendocrine system and hypothalamus is the main center for energy homeostasis. The mechanical or functional disruption of the hypothalamic network that regulates this system causes intractable weight gain. The pathogenetic mechanisms underlying HO are complex and multifactorial. Weight gain results from damage to the ventromedial hypothalamus, which may lead to hyperphagia, a low resting metabolic rate, autonomic imbalance, growth hormone, gonadotropin, and thyroid-stimulating hormone deficiencies, hypomobility, and insomnia. Disruption of leptin signaling and decreased central sympathetic output seem to have a critical role in the development of HO.
Hypothalamic Obesity Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Hypothalamic Obesity targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Hypothalamic Obesity pipeline report covers 10+ companies. Some of the key players include Saniona (Tesomet), Amylin Pharmaceuticals/Astrazeneca (Exenatide) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Hypothalamic Obesity Analytical Perspective by DelveInsight
• In-depth Hypothalamic Obesity Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Hypothalamic Obesity Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Hypothalamic Obesity report provides an overview of therapeutic pipeline activity for Hypothalamic Obesity across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Hypothalamic Obesity therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Hypothalamic Obesity Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hypothalamic Obesity
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Hypothalamic Obesity to formulate effective R&D strategies
• Assess challenges and opportunities that influence Hypothalamic Obesity R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Hypothalamic Obesity in licensing and out licensing strategies by identifying prospective partners with progressing projects for Hypothalamic Obesity to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugsPlease Note: The report will be delivered in 2-3 business days upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook